Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial - Université de Bretagne Occidentale Access content directly
Journal Articles The Lancet Haematology Year : 2016

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Gary Raskob
  • Function : Author
Nick van Es
  • Function : Author
Annelise Segers
  • Function : Author
Pantep Angchaisuksiri
  • Function : Author
Doyeun Oh
  • Function : Author
Roger Lyons
  • Function : Author
Karina Meijer
  • Function : Author
  • PersonId : 910627
Ivan Gudz
  • Function : Author
George Zhang
  • Function : Author
Hans Lanz
  • Function : Author
Michele Mercuri
  • Function : Author
Harry Büller
  • Function : Author
No file

Dates and versions

hal-02043621 , version 1 (21-02-2019)

Identifiers

  • HAL Id : hal-02043621 , version 1

Cite

Gary Raskob, Nick van Es, Annelise Segers, Pantep Angchaisuksiri, Doyeun Oh, et al.. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. The Lancet Haematology, 2016, 3 (8), pp.e379-e387. ⟨hal-02043621⟩
38 View
0 Download

Share

Gmail Mastodon Facebook X LinkedIn More